

# Nitrate in Type 2 Diabetes

Subjects: Medicine, General & Internal

Submitted by:  Khosrow Kashfi

## Definition

Beneficial metabolic effects of inorganic nitrate ( $\text{NO}_3^-$ ) and nitrite ( $\text{NO}_2^-$ ) in type 2 diabetes mellitus (T2DM) have been documented in animal experiments; however, this is not the case for humans. Although it has remained an open question, the redox environment affecting the conversion of  $\text{NO}_3^-$  to  $\text{NO}_2^-$  and then to NO is suggested as a potential reason for this lost-in-translation. Ascorbic acid (AA) has a critical role in the gastric conversion of  $\text{NO}_2^-$  to NO following ingestion of  $\text{NO}_3^-$ . In contrast to AA-synthesizing species like rats, the lack of ability to synthesize AA and a lower AA body pool and plasma concentrations may partly explain why humans with T2DM do not benefit from  $\text{NO}_3^-/\text{NO}_2^-$  supplementation. Rats also have higher AA concentrations in their stomach tissue and gastric juice that can significantly potentiate gastric  $\text{NO}_2^-$ -to-NO conversion.

---

## 1. Introduction

Inorganic nitrate ( $\text{NO}_3^-$ ) and nitrite ( $\text{NO}_2^-$ ) are considered storage pools for nitric oxide (NO)-like bioactivity that complement or alternate the NO synthase (NOS)-dependent pathway [1]. The biological importance of the  $\text{NO}_3^-$ - $\text{NO}_2^-$ -NO pathway is more highlighted where the NOS system is compromised, e.g., in cardiometabolic diseases [2][3].

Type 2 diabetes mellitus (T2DM), a metabolic disorder complicated with disrupted NO metabolism [4][5], has recently been targeted for inorganic  $\text{NO}_3^-$ - $\text{NO}_2^-$  therapy. Supplementation of diets rich in inorganic  $\text{NO}_3^-$ - $\text{NO}_2^-$  has received increased attention as being effective in improving glucose and insulin homeostasis in animal models of T2DM [6][7][8][9][10]. Favorable effects of  $\text{NO}_3^-$  therapy on glucose and insulin homeostasis were surprisingly comparable to metformin therapy, a drug used as the first-line anti-diabetic agent [11].

In contrast to animal experiments, controversy surrounds the  $\text{NO}_3^-$ - $\text{NO}_2^-$  efficacy on metabolic parameters in humans with T2DM. These interventions have failed to show any beneficial effects on glucose and insulin parameters. Although some plausible explanations have been provided, the reason for this lost-in-translation remains an open question. Species-differences in  $\text{NO}_3^-$ - $\text{NO}_2^-$  metabolism, due to differences in the gut-oral microbiota, and the redox environment affecting the capacity of  $\text{NO}_3^-$  to  $\text{NO}_2^-$  to NO reduction (e.g., oral and stomach pH, reducing agents like ascorbic acid (AA), and  $\text{NO}_3^-$ - $\text{NO}_2^-$  reductase enzymes) may explain the failure of the data to translate from animals to humans. Furthermore, some confounding variables such as doses and forms of  $\text{NO}_3^-$  and  $\text{NO}_2^-$  supplementation, age of the experimental units [12], background dietary intake of  $\text{NO}_3^-$ - $\text{NO}_2^-$ , and use of anti-diabetic drugs in humans [11][13] can also influence the magnitude of the metabolic response to  $\text{NO}_3^-$ - $\text{NO}_2^-$  therapy in humans with T2DM.

## 2. A Brief Overview of $\text{NO}_3^-$ - $\text{NO}_2^-$ -NO Pathway

There are two major pathways for NO production in humans: (i) the classic L-arginine-NOS pathway, in which NO is produced from L-arginine by three isoforms of NOS, namely, endothelial (eNOS), neural (nNOS), and inducible (iNOS) NOSs, and (ii)  $\text{NO}_3^-$ - $\text{NO}_2^-$ -NO pathway, in which  $\text{NO}_3^-$  is reduced to  $\text{NO}_2^-$  and then to NO [2]. The  $\text{NO}_3^-$ - $\text{NO}_2^-$ -NO pathway has a compensatory role in maintaining basal levels of NO in the absolute absence of the NOS system (i.e., triple NOS-knockout model), thus keeping the animals alive [14]. There is negative cross-talk between the two pathways in maintaining NO homeostasis [1][15]. Chronic  $\text{NO}_3^-$  supplementation may reversibly and dose-dependently reduce eNOS activity; on the other hand, responses to exogenous  $\text{NO}_3^-$ - $\text{NO}_2^-$  depend upon the basal eNOS activity, and subjects with deficient eNOS activity and vascular NO deficiency may, therefore, have an augmented

response to these anions [1][15]. Several dietary factors, including dietary antioxidants, polyphenols, and fatty acids, may affect the NO pathway in humans [16]. Furthermore, dietary antioxidant capacity and vitamin C intake may modify the potential effects of  $\text{NO}_3^-$ - $\text{NO}_2^-$  in cardiometabolic diseases [17][18].

Major sources of  $\text{NO}_3^-$  in humans are endogenously derived from NO oxidation and exogenously derived from the diet. About 50% of steady-state circulating NO metabolites are derived from dietary sources [19]; the acceptable daily intake (ADI) values are 3.7 and 0.06 mg/kg body weight for  $\text{NO}_3^-$  and  $\text{NO}_2^-$ , respectively [20]. Following ingestion, inorganic  $\text{NO}_3^-$  passes from the mouth into the stomach and is then absorbed into the blood from the proximal small intestine [21]. In humans, about 50–90% [22][23][24] (a mean of 75% [25]) of ingested  $\text{NO}_3^-$  is excreted in the urine, with negligible fecal excretion [26].  $\text{NO}_3^-$  recovery from urine was reported to be about 35–65% of the oral doses in rats and rabbits [21][27]. About 25% of ingested  $\text{NO}_3^-$  is taken up from the plasma [28] by the salivary glands, probably via the sialin transporter [29], concentrated by 10–20 folds, and secreted in the saliva [29][30], a process that is called enterosalivary circulation of  $\text{NO}_3^-$  [28]. Unlike humans, the active secretion of  $\text{NO}_3^-$  into the saliva does not occur in rats and mice [31]; however, the entero-systemic cycling of  $\text{NO}_3^-$  may occur in these species by secreting from the circulation into the other parts of the gastrointestinal system, including the gastric and intestinal secretions via an active transport process [32].

Upon entering the mouth, oral  $\text{NO}_3^-$ -reducing bacteria converts about 20% of the dietary  $\text{NO}_3^-$  to  $\text{NO}_2^-$  [28]. This pathway is the most important source of  $\text{NO}_2^-$  in the human body [33] and provides systemic delivery of substrate for NO generation. Oral  $\text{NO}_3^-$ -reduction results in an average of  $85.4 \pm 15.9$  nmol  $\text{NO}_2^-$  per min [34]. The oral  $\text{NO}_3^-$ -reducing bacteria are mostly resident at the dorsal surface of the tongue both in humans and rats [34][35]. The critical role of  $\text{NO}_3^-$ -reducing bacteria on the  $\text{NO}_3^-$ - $\text{NO}_2^-$ -NO pathway and systemic NO availability is highlighted by the data showing that circulating  $\text{NO}_2^-$  is decreased and NO-mediated biological effects are partially or entirely prevented when the oral microbiome was abolished via antiseptic mouthwash [36][37][38]. Although the rat tongue microbiome is less diverse than the human, the physiological activity of the oral microbiome is comparable in both species [39].

Salivary  $\text{NO}_2^-$  reaching the stomach is rapidly converted to NO in the presence of acidic gastric juice and AA and diffuses into the circulation [40][41]. Inorganic  $\text{NO}_3^-$  can therefore act as a substrate for further systemic generation of bioactive NO [30]. The efficiency of sequential reduction of inorganic  $\text{NO}_3^-$  into  $\text{NO}_2^-$  and then into NO depends on the capacity of the salivary glands to concentrate  $\text{NO}_3^-$ , oral  $\text{NO}_3^-$ -reducing bacteria, gastric AA concentration and the redox environment,  $\text{O}_2$  pressure, pH in the peripheral circulation, and the efficiency of the enzymatic reductase activity (i.e., deoxyhemoglobin, aldehyde dehydrogenase, and xanthine oxidase) [1]; these factors may affect the metabolic response to oral dosing of inorganic  $\text{NO}_3^-$ .

### 3. Effects of Inorganic $\text{NO}_3^-$ and $\text{NO}_2^-$ in Type 2 Diabetes

Impaired NO metabolism, including decreased eNOS-derived NO bioavailability, over-production of iNOS-derived NO, and impaired  $\text{NO}_3^-$ - $\text{NO}_2^-$ -NO pathway, are involved in T2DM development [42], hypertension [43], and cardiovascular diseases [44]. Increased NO bioavailability using NO precursors, including L-arginine [45][46], L-citrulline [47], or inorganic  $\text{NO}_3^-$  and  $\text{NO}_2^-$  has been suggested as complementary treatments in T2DM [48][49][50]. Due to lack of efficacy [51] and safety [52] of long-term L-arginine supplementation and undesirable side effects (i.e., induction of arginase activity [53][54], increased urea levels [55], suppression of eNOS expression and activity, and induction of cellular oxidative stress [56]), inorganic  $\text{NO}_3^-$  and  $\text{NO}_2^-$  have received much attention as NO-boosting supplements.

Inorganic  $\text{NO}_3^-$  and  $\text{NO}_2^-$  improve glucose and insulin homeostasis in animal models of T2DM [6][7][8][9][10]; supplementation with these anions decreases hyperglycemia and improves insulin sensitivity and glucose tolerance [9][10].  $\text{NO}_3^-$  and  $\text{NO}_2^-$  increase insulin secretion by increasing pancreatic blood flow [57], increasing pancreatic islet insulin content [7], and increased gene expression of proteins involved in exocytosis of insulin in isolated pancreatic islets [58].  $\text{NO}_3^-$  and  $\text{NO}_2^-$  increase insulin

sensitivity by increasing GLUT4 expression and protein levels in epididymal adipose tissue [6], skeletal muscle [7], and its translocation into the cell membrane [9], increasing browning of white adipose tissue [59], decreasing adipocyte size [9], as well as improving inflammation, dyslipidemia, liver steatosis, and oxidative stress [3][7][60]. **Table 1** summarizes the effects of NO<sub>3</sub><sup>-</sup>-NO<sub>2</sub><sup>-</sup> therapy on glucose and insulin homeostasis and diabetes-induced cardiometabolic disorders in animal models of T2DM. More details about the favorable metabolic effects of NO<sub>3</sub><sup>-</sup> and NO<sub>2</sub><sup>-</sup> can be found in published reviews [2][3][61].

**Table 1.** The effects of NO<sub>3</sub><sup>-</sup> and NO<sub>2</sub><sup>-</sup> on glucose and insulin homeostasis, and cardiometabolic disorders in experimental models of type 2 diabetes mellitus and insulin resistance.

Author	Model	Treatment	Outcomes
Jeddi et al., 2021 [62]	High-fat diet + low-dose of STZ (30 mg/kg body weight), male rats	100 mg/L NaNO <sub>3</sub> in drinking water for 6 months	<ul style="list-style-type: none"> <li>↓ Serum glucose by 13%</li> <li>↓ Serum insulin by 23%</li> <li>↑ cGMP level in epididymal adipose tissue by 85%</li> <li>↑ Adipocyte density by 193% (epididymal adipose tissue)</li> <li>↓ Adipocyte area by 53% (epididymal adipose tissue)</li> <li>↑ Expression of browning genes in epididymal adipose tissue (↑ mRNA and protein levels of PPAR-γ, PGC1-α, and UCP-1 to their normal values)</li> </ul>
Tian et al., 2020 [63]	High-fat diet + low dose of STZ (20 mg/kg body weight), male mice	255 mg/L NaNO <sub>3</sub> in drinking water for 8 weeks	<ul style="list-style-type: none"> <li>↓ Fasting glucose</li> <li>Prevention of impaired glucose tolerance (measured by IP-GTT), Prevention of insulin resistance (measured by IP-ITT)</li> <li>↓ Systolic blood pressure</li> <li>↓ Vascular oxidative stress (↓ ROS formation)</li> <li>↓ NADPH oxidase activity via induction of HO-1 and reduction in p47phox expression</li> <li>Improvement of endothelial function (ACh-mediated vascular relaxation)</li> <li>Improvement of inflammation and dyslipidemia</li> <li>↓ Development of aortic atherosclerosis</li> </ul>
Aggarwal et al., 2020 [64]	Insulin-resistant iNOS <sup>-/-</sup> male mice	50 mg/L NaNO <sub>2</sub> in drinking water for 5 weeks	<ul style="list-style-type: none"> <li>Improved glucose tolerance (measured by IP-GTT)</li> <li>Improved insulin resistance (measured by IP-ITT)</li> <li>Partially reversed up-regulated gluconeogenesis (↓ expression of PEPCK, G6P, and PC)</li> <li>Restored total Akt (PKB) expression in the liver and adipose tissue</li> <li>Restored decreased Akt-1/2/3 phosphorylation (Ser473) in the liver</li> <li>Improved insulin signaling in the adipose tissue</li> </ul>
Norouzirad et al., 2019 [65]	High-fat diet + low dose of STZ (30 mg/kg body weight), male rats	100 mg/L NaNO <sub>3</sub> in drinking water for 5 weeks	<ul style="list-style-type: none"> <li>↓ Fasting glucose</li> <li>↓ Gluconeogenesis (measured by IP-PTT)</li> <li>Improved glucose tolerance</li> <li>Restored CAT activity to near normal value</li> <li>Restored elevated TOS to near normal value</li> <li>Restored decreased TAC levels to near normal value</li> <li>↑ Serum SOD, GSH, and GSH-to-GSSG ratio</li> </ul>
Gheibi et al., 2018 [6]	High-fat diet + low dose of STZ (25 mg/g body weight), male rats	100 mg/L NaNO <sub>3</sub> in drinking water for 8 weeks	<ul style="list-style-type: none"> <li>↓ Serum glucose and insulin, ↔ HbA1c</li> <li>↑ Glucose tolerance (measured by IP-GTT)</li> <li>↑ Insulin sensitivity (measured by QUICKI)</li> <li>↓ Gluconeogenesis (measured by IP-PTT)</li> <li>↑ GLUT4 mRNA expression and protein levels in the soleus muscle by 215% and 17%</li> <li>↑ GLUT4 mRNA expression and protein levels in the epididymal adipose tissue by 344% and 22%</li> <li>↔ GSIS, islet insulin content</li> <li>↑ Serum CAT activity, ↓ Serum IL-1β</li> <li>↔ Serum TBARS</li> <li>↓ Elevated iNOS mRNA expression in the soleus muscle and epididymal adipose tissue</li> </ul>

Author	Model	Treatment	Outcomes
Gheibi et al., 2017 [7]	High-fat diet + low dose of STZ (30 mg/kg body weight), male rats	50 mg/L NaNO <sub>2</sub> in drinking water for 8 weeks	↑ GSIS (by 34%), ↔ BIS ↑ Protein levels of GLUT4 in the soleus muscle and epididymal adipose tissue by 22% and 26% Improved glucose tolerance (measured by IP-GTT) and insulin sensitivity (measured by IP-ITT and QUICKI) ↓ Insulin resistance (measured by HOMA-IR) ↓ Fasting serum glucose and insulin, ↔ HbA1c Restored pancreatic insulin content to 73% of controls (68.2 ± 6.4 vs. 117 ± 6.0 pmol/mg protein) Restored elevated serum levels of TC, TG, and LDL-C ↔ HDL-C
Ohtake et al., 2015 [9]	KKAY diabetic male mice	50 and 150 mg/L nitrite in drinking water for 10 weeks	↓ Fasting glucose ↓ Insulin resistance (measured by HOMA-IR) Improved glucose tolerance (measured by IP-GTT) ↑ GLUT4 expression on the cell membrane of the skeletal muscle
Khalifi et al., 2015 [8]	STZ (65 mg/kg) + nicotinamide (95 mg/kg), male rats	100 mg/L NaNO <sub>3</sub> in drinking water for 8 weeks	Improved glucose tolerance (measured as IV-GTT) ↓ Serum TC (23.6%), TG (24.2%), and LDL-C (28.8%) ↑ Serum HDL-C (42.4%) Restored TAC and CAT levels to normal values
Jiang et al., 2014 [66]	db/db diabetic male mice	50 mg/L NaNO <sub>2</sub> in drinking water for 4 weeks	↓ Fasting glucose (by 35%) ↓ Plasma insulin
Carlstrom et al., 2010 [10]	eNOS-deficient female mice	85 mg/L NaNO <sub>3</sub> in drinking water for 8–10 weeks	↓ HbA1c, Fasting glucose ↓ Pro-insulin to insulin ratio ↑ Glucose tolerance (measured by IP-GTT)

↔, no change; ↑, increase; ↓, decrease. ACh, acetylcholine; BIS, basal insulin secretion; CAT, catalase; cGMP, cyclic guanosine monophosphate; eNOS, endothelial nitric oxide synthase; G6P, glucose-6-phosphatase; GSH, reduced glutathione; GSIS, glucose-stimulated insulin secretion; GSSG, oxidized glutathione; HbA1C, glycated hemoglobin; HDL-C, high-density lipoprotein-cholesterol; HO-1; heme oxygenase-1; HOMA-IR, homeostasis model assessment of insulin resistance; IL-1β, interleukin -1β; iNOS, inducible NOS; IP-GTT, intraperitoneal glucose tolerance test; IP-ITT, intraperitoneal insulin tolerance test; IP-PTT, intraperitoneal pyruvate tolerance test; IV-GTT, intravenous glucose tolerance test; LDL-C, low-density lipoprotein-cholesterol; NADPH, nicotinamide adenine dinucleotide phosphate oxidase; PC, pyruvate carboxylase; PEPCK, phosphoenolpyruvate carboxykinase; PGC1-α, PPAR-γ coactivator 1 alpha; PPAR-γ, peroxisome proliferator activated receptor gamma; phox, phagocyte oxidase; QUICKI, quantitative insulin-sensitivity check index; ROS, reactive oxygen species; SOD, superoxide dismutase; STZ, streptozotocin; TAC, total antioxidant capacity; TBARS, thiobarbituric reactive substances; TG, triglycerides; TOS, total oxidant status; TC, total cholesterol; UCP-1, uncoupling protein 1.

Despite being effective in animal models of T2DM, as it is summarized in [Table 2](#), all acute [67], mid-term [68][69], and long-term [70][71][72] oral dosing of inorganic NO<sub>3</sub><sup>-</sup> and NO<sub>2</sub><sup>-</sup>, either as pharmacological forms (i.e., KNO<sub>3</sub>, NaNO<sub>3</sub>, and NaNO<sub>2</sub>) or food-based supplementation (i.e., NO<sub>3</sub><sup>-</sup>-rich beetroot juice or powder) have failed to show beneficial effects on glucose and insulin parameters, including fasting and postprandial serum glucose and insulin concentrations, insulin resistance indices, and HbA1c levels in patients with T2DM. However, ergogenic [73][74] and beneficial cardiovascular effects of inorganic NO<sub>3</sub><sup>-</sup> and NO<sub>2</sub><sup>-</sup>, e.g., reducing peripheral and central systolic and diastolic blood pressures [75], have been highlighted in non-diabetic subjects by several clinical studies.

**Table 2.** Cardiometabolic effects of inorganic NO<sub>3</sub><sup>-</sup>-NO<sub>2</sub><sup>-</sup> in patients with type 2 diabetes mellitus: findings of clinical trials.

Study	Intervention	Outcomes
Bahadoran et al., 2021 [76]	NO <sub>3</sub> <sup>-</sup> -rich beetroot powder (250 mg/day NO <sub>3</sub> <sup>-</sup> ), for 24 weeks	<ul style="list-style-type: none"> <li>↔ Fasting glucose, HbA1c, insulin, C-peptide</li> <li>↔ HOMA-IR, QUICKI</li> <li>↔ Serum lipid parameters</li> <li>↔ Serum ALT, AST, ALP, GGT</li> <li>↔ Serum creatinine and uric acid</li> <li>↔ Urinary creatinine and albumin</li> </ul>
Faconti et al., 2019 [70] and Mills et al. [71]	NO <sub>3</sub> <sup>-</sup> -containing beetroot juice (279 mg/day NO <sub>3</sub> <sup>-</sup> ), for 24 weeks	<ul style="list-style-type: none"> <li>↔ SBP, DBP</li> <li>↔ Arterial stiffness</li> <li>↔ Fasting glucose, HbA1c</li> <li>↓ Left ventricular end-diastolic and end-systolic volume</li> </ul>
Soin et al., 2018 [72]	40 and 80 mg/day sustained-release formulation NaNO <sub>2</sub> , for 12 weeks	<ul style="list-style-type: none"> <li>↔ HbA1c</li> <li>Improvement of neuropathic pain</li> </ul>
Shepherd et al., 2015 [77]	70 mL/day NO <sub>3</sub> <sup>-</sup> -containing beetroot juice (398 mg/day NO <sub>3</sub> <sup>-</sup> ), for 4 days	<ul style="list-style-type: none"> <li>↔ SBP, DBP</li> <li>↔ Oxygen cost of exercise</li> <li>↔ Walking performance (6-min walk test)</li> </ul>
Cermak et al., 2015 [67]	An acute dose of NaNO <sub>3</sub> (12.75 mg/kg body weight)	<ul style="list-style-type: none"> <li>↔ Postprandial glucose and insulin response to 75-g glucose</li> <li>↑ OGIS index</li> <li>↔ HOMA-IR</li> </ul>
Mohler et al., 2014 [78]	40 and 80 mg/day NaNO <sub>2</sub> , for 10 weeks	<ul style="list-style-type: none"> <li>↑ FMD at a dose of 80 mg/day</li> </ul>
Gilchrist et al., 2014 [68]	250 mL/day beetroot juice (465 mg/d NO <sub>3</sub> <sup>-</sup> ), for 2 weeks	<ul style="list-style-type: none"> <li>↔ Fasting glucose, HbA1c</li> <li>↔ Cognitive function</li> <li>Improvement in simple reaction time</li> </ul>

Study	Intervention	Outcomes
Gilchrist et al., 2013 [69]	250 mL/day beetroot juice (465 mg/d NO <sub>3</sub> <sup>-</sup> ), for 2 weeks	↔ SBP, DBP  ↔ Macro-(FMD) and micro-(ACh-induced vasodilation) vascular function  ↔ Insulin sensitivity (hyperinsulinemic-euglycemic clamp technique)
Greenway et al., 2012 [79]	An acute dose of 80 mg of NaNO <sub>2</sub> (IR and EC formulation)	↓ SPB and DBP in IR  ↔ SPB and DBP in EC

↔, no change; ↑, increase; ↓, decrease; ACh, acetylcholine; ALP, alkaline phosphatase; ALT, alanine transaminase; AST, aspartate transaminase; C-peptide, connecting peptide; DBP, diastolic blood pressure; EC, enteric-coated formulation; FMD, flow-mediated dilation; GGT;  $\gamma$ -glutamyl transpeptidase; HbA1C, glycated hemoglobin; HOMA-IR, homeostasis model assessment of insulin resistance; IR, immediate-release formulation; OGIS, oral glucose insulin sensitivity; QUICKI, quantitative insulin sensitivity check index; SBP, systolic blood pressure.

## References

- Lundberg, J.O.; Weitzberg, E.; Gladwin, M.T. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. *Nat. Rev. Drug Discov.* 2008, 7, 156-167.
- Ghasemi, A.; Jeddi, S. Anti-obesity and anti-diabetic effects of nitrate and nitrite. *Nitric Oxide Biol. Chem.* 2017, 70, 9-24.
- Lundberg, J.O.; Carlstrom, M.; Weitzberg, E. Metabolic Effects of Dietary Nitrate in Health and Disease. *Cell Metab.* 2018, 28, 9-22.
- Tessari, P.; Cecchet, D.; Cosma, A.; Vettore, M.; Coracina, A.; Millioni, R.; Iori, E.; Puricelli, L.; Avogaro, A.; Vedovato, M. Nitric Oxide Synthesis Is Reduced in Subjects With Type 2 Diabetes and Nephropathy. *Diabetes* 2010, 59, 2152-2159.
- Natali, A.; Ribeiro, R.; Baldi, S.; Tulipani, A.; Rossi, M.; Venturi, E.; Mari, A.; Macedo, M.P.; Ferrannini, E. Systemic inhibition of nitric oxide synthesis in non-diabetic individuals produces a significant deterioration in glucose tolerance by increasing insulin clearance and inhibiting insulin secretion. *Diabetologia* 2013, 56, 1183-1191.
- Gheibi, S.; Jeddi, S.; Carlström, M.; Gholami, H.; Ghasemi, A. Effects of long-term nitrate supplementation on carbohydrate metabolism, lipid profiles, oxidative stress, and inflammation in male obese type 2 diabetic rats. *Nitric Oxide Biol. Chem.* 2018, 75, 27-41.
- Gheibi, S.; Bakhtiarzadeh, F.; Jeddi, S.; Farrokhfall, K.; Zardooz, H.; Ghasemi, A. Nitrite increases glucose-stimulated insulin secretion and islet insulin content in obese type 2 diabetic male rats. *Nitric Oxide Biol. Chem.* 2017, 64, 39-51.
- Khalifi, S.; Rahimipour, A.; Jeddi, S.; Ghanbari, M.; Kazerouni, F.; Ghasemi, A. Dietary nitrate improves glucose tolerance and lipid profile in an animal model of hyperglycemia. *Nitric Oxide Biol. Chem.* 2015, 44, 24-30.
- Ohtake, K.; Nakano, G.; Ehara, N.; Sonoda, K.; Ito, J.; Uchida, H.; Kobayashi, J. Dietary nitrite supplementation improves insulin resistance in type 2 diabetic KKA(y) mice. *Nitric Oxide Biol. Chem.* 2015, 44, 31-38.
- Carlstrom, M.; Larsen, F.J.; Nystrom, T.; Hezel, M.; Borniquel, S.; Weitzberg, E.; Lundberg, J.O. Dietary inorganic nitrate reverses features of metabolic syndrome in endothelial nitric oxide synthase-deficient mice. *Proc. Natl. Acad. Sci. USA* 2010, 107, 17716-17720.
- Cordero-Herrera, I.; Guimarães, D.D.; Moretti, C.; Zhuge, Z.; Han, H.; McCann Haworth, S.; Uribe Gonzalez, A.E.; Andersson, D.C.; Weitzberg, E.; Lundberg, J.O.; et al. Head-to-head comparison of inorganic nitrate and metformin in a mouse model of cardiometabolic disease. *Nitric Oxide Biol. Chem.* 2020, 97, 48-56.
- Siervo, M.; Lara, J.; Jajja, A.; Sutjarjoko, A.; Ashor, A.W.; Brandt, K.; Qadir, O.; Mathers, J.C.; Benjamin, N.; Winyard,

- P.G.; et al. Ageing modifies the effects of beetroot juice supplementation on 24-hour blood pressure variability: An individual participant meta-analysis. *Nitric Oxide Biol. Chem.* 2015, 47, 97–105.
13. Sambe, T.; Mason, R.P.; Dawoud, H.; Bhatt, D.L.; Malinski, T. Metformin treatment decreases nitroxidative stress, restores nitric oxide bioavailability and endothelial function beyond glucose control. *Biomed. Pharmacother.* 2018, 98, 149–156.
  14. Milsom, A.B.; Fernandez, B.O.; Garcia-Saura, M.F.; Rodriguez, J.; Feelisch, M. Contributions of nitric oxide synthases, dietary nitrite/nitrate, and other sources to the formation of NO signaling products. *Antioxid Redox Signal* 2012, 17, 422–432.
  15. Carlström, M.; Liu, M.; Yang, T.; Zollbrecht, C.; Huang, L.; Peleli, M.; Borniquel, S.; Kishikawa, H.; Hezel, M.; Persson, A.E.G.; et al. Cross-talk Between Nitrate-Nitrite-NO and NO Synthase Pathways in Control of Vascular NO Homeostasis. *Antioxid Redox Signal* 2015, 23, 295–306.
  16. Wong, W.T.; Cooke, J.P. Nutritional Impact on the Nitric Oxide Pathway. In *Nitrite and Nitrate in Human Health and Disease*; Springer: Berlin/Heidelberg, Germany, 2011; pp. 97–122.
  17. Bahadoran, Z.; Mirmiran, P.; Ghasemi, A.; Carlström, M.; Azizi, F.; Hadaegh, F. Vitamin C intake modify the impact of dietary nitrite on the incidence of type 2 diabetes: A 6-year follow-up in Tehran Lipid and Glucose Study. *Nitric Oxide Biol. Chem.* 2017, 62, 24–31.
  18. Bahadoran, Z.; Carlström, M.; Ghasemi, A.; Mirmiran, P.; Azizi, F.; Hadaegh, F. Total antioxidant capacity of the diet modulates the association between habitual nitrate intake and cardiovascular events: A longitudinal follow-up in Tehran Lipid and Glucose Study. *Nutr. Metab.* 2018, 15, 19.
  19. Hord, N.G.; Tang, Y.; Bryan, N.S. Food sources of nitrates and nitrites: The physiologic context for potential health benefits. *Am. J. Clin. Nutr.* 2009, 90, 1–10.
  20. Gangolli, S.D.; Van Den Brandt, P.A.; Feron, V.J.; Janzowsky, C.; Koeman, J.H.; Speijers, G.J.; Spiegelhalder, B.; Walker, R.; Wishnok, J.S. Nitrate, nitrite and N-nitroso compounds. *Eur. J. Pharmacol. Environ. Toxicol. Pharmacol.* 1994, 292, 1–38.
  21. Schultz, D.S.; Deen, W.M.; Karel, S.F.; Wagner, D.A.; Tannenbaum, S.R. Pharmacokinetics of nitrate in humans: Role of gastrointestinal absorption and metabolism. *Carcinogenesis* 1985, 6, 847–852.
  22. Wagner, D.A.; Schultz, D.S.; Deen, W.M.; Young, V.R.; Tannenbaum, S.R. Metabolic fate of an oral dose of 15N-labeled nitrate in humans: Effect of diet supplementation with ascorbic acid. *Cancer Res.* 1983, 43, 1921–1925.
  23. Ellen, G.; Schuller, P.L.; Bruijns, E.; Froeling, P.G.; Baadenhuijsen, H.U. Volatile N-nitrosamines, nitrate and nitrite in urine and saliva of healthy volunteers after administration of large amounts of nitrate. *IARC Sci. Publ.* 1982, 41, 365–378.
  24. Radomski, J.L.; Palmiri, C.; Hearn, W.L. Concentrations of nitrate in normal human urine and the effect of nitrate ingestion. *Toxicol. Appl. Pharmacol.* 1978, 45, 63–68.
  25. Pannala, A.S.; Mani, A.R.; Spencer, J.P.; Skinner, V.; Bruckdorfer, K.R.; Moore, K.P.; Rice-Evans, C.A. The effect of dietary nitrate on salivary, plasma, and urinary nitrate metabolism in humans. *Free Radic. Biol. Med.* 2003, 34, 576–584.
  26. Saul, R.L.; Kabir, S.H.; Cohen, Z.; Bruce, W.R.; Archer, M.C. Reevaluation of Nitrate and Nitrite Levels in the Human Intestine. *Cancer Res.* 1981, 41, 2280–2283.
  27. Mitchell, H.; Shonle, H.; Grindley, H. The origin of the nitrates in the urine. *J. Biol. Chem.* 1916, 24, 461–490.
  28. Spiegelhalder, B.; Eisenbrand, G.; Preussmann, R. Influence of dietary nitrate on nitrite content of human saliva: Possible relevance to in vivo formation of N-nitroso compounds. *Food Cosmet. Toxicol.* 1976, 14, 545–548.
  29. Qin, L.; Liu, X.; Sun, Q.; Fan, Z.; Xia, D.; Ding, G.; Ong, H.L.; Adams, D.; Gahl, W.A.; Zheng, C.; et al. Sialin (SLC17A5) functions as a nitrate transporter in the plasma membrane. *Proc. Natl. Acad. Sci. USA* 2012, 109, 13434–13439.
  30. Lundberg, J.O.; Govoni, M. Inorganic nitrate is a possible source for systemic generation of nitric oxide. *Free Radic. Biol. Med.* 2004, 37, 395–400.
  31. Montenegro, M.F.; Sundqvist, M.L.; Nihlén, C.; Hezel, M.; Carlström, M.; Weitzberg, E.; Lundberg, J.O. Profound differences between humans and rodents in the ability to concentrate salivary nitrate: Implications for translational research. *Redox Biol.* 2016, 10, 206–210.
  32. Witter, J.P.; Balish, E. Distribution and metabolism of ingested NO<sub>3</sub><sup>-</sup> and NO<sub>2</sub><sup>-</sup> in germfree and conventional-flora rats. *Appl. Environ. Microbiol.* 1979, 38, 861–869.
  33. Walker, R. The metabolism of dietary nitrites and nitrates. *Biochem. Soc. Trans.* 1996, 24, 780–785.
  34. Doel, J.J.; Benjamin, N.; Hector, M.P.; Rogers, M.; Allaker, R.P. Evaluation of bacterial nitrate reduction in the human oral cavity. *Eur. J. Oral Sci.* 2005, 113, 14–19.
  35. Li, H.; Duncan, C.; Townend, J.; Killham, K.; Smith, L.M.; Johnston, P.; Dykhuizen, R.; Kelly, D.; Golden, M.; Benjamin, N.; et al. Nitrate-reducing bacteria on rat tongues. *Appl. Environ. Microbiol.* 1997, 63, 924–930.
  36. Kapil, V.; Haydar, S.M.; Pearl, V.; Lundberg, J.O.; Weitzberg, E.; Ahluwalia, A. Physiological role for nitrate-reducing oral bacteria in blood pressure control. *Free Radic. Biol. Med.* 2013, 55, 93–100.
  37. Petersson, J.; Carlström, M.; Schreiber, O.; Phillipson, M.; Christoffersson, G.; Jägare, A.; Roos, S.; Jansson, E.A.; Persson, A.E.; Lundberg, J.O.; et al. Gastroprotective and blood pressure lowering effects of dietary nitrate are



- abolished by an antiseptic mouthwash. *Free Radic. Biol. Med.* 2009, 46, 1068–1075.
38. Govoni, M.; Jansson, E.A.; Weitzberg, E.; Lundberg, J.O. The increase in plasma nitrite after a dietary nitrate load is markedly attenuated by an antibacterial mouthwash. *Nitric Oxide Biol. Chem.* 2008, 19, 333–337.
  39. Hyde, E.R.; Luk, B.; Cron, S.; Kusic, L.; McCue, T.; Bauch, T.; Kaplan, H.; Tribble, G.; Petrosino, J.F.; Bryan, N.S. Characterization of the rat oral microbiome and the effects of dietary nitrate. *Free Radic. Biol. Med.* 2014, 77, 249–257.
  40. McKnight, G.M.; Smith, L.M.; Drummond, R.S.; Duncan, C.W.; Golden, M.; Benjamin, N. Chemical synthesis of nitric oxide in the stomach from dietary nitrate in humans. *Gut* 1997, 40, 211–214.
  41. Iijima, K.; Fyfe, V.; McColl, K.E. Studies of nitric oxide generation from salivary nitrite in human gastric juice. *Scand. J. Gastroenterol.* 2003, 38, 246–252.
  42. Bahadoran, Z.; Mirmiran, P.; Ghasemi, A. Role of Nitric Oxide in Insulin Secretion and Glucose Metabolism. *Trends Endocrinol. Metab. TEM* 2020, 31, 118–130.
  43. Hsu, C.-N.; Tain, Y.-L. Regulation of Nitric Oxide Production in the Developmental Programming of Hypertension and Kidney Disease. *Int. J. Mol. Sci.* 2019, 20, 681.
  44. Chen, J.-Y.; Ye, Z.-X.; Wang, X.-F.; Chang, J.; Yang, M.-W.; Zhong, H.-H.; Hong, F.-F.; Yang, S.-L. Nitric oxide bioavailability dysfunction involves in atherosclerosis. *Biomed. Pharmacother.* 2018, 97, 423–428.
  45. Hu, S.; Han, M.; Rezaei, A.; Li, D.; Wu, G.; Ma, X. L-Arginine Modulates Glucose and Lipid Metabolism in Obesity and Diabetes. *Curr. Protein Pept. Sci.* 2017, 18, 599–608.
  46. Piatti, P.M.; Monti, L.D.; Valsecchi, G.; Magni, F.; Setola, E.; Marchesi, F.; Galli-Kienle, M.; Pozza, G.; Alberti, K.G. Long-term oral L-arginine administration improves peripheral and hepatic insulin sensitivity in type 2 diabetic patients. *Diabetes Care* 2001, 24, 875–880.
  47. Azizi, S.; Mahdavi, R.; Vaghef-Mehrabany, E.; Maleki, V.; Karamzad, N.; Ebrahimi-Mameghani, M. Potential roles of Citrulline and watermelon extract on metabolic and inflammatory variables in diabetes mellitus, current evidence and future directions: A systematic review. *Clin. Exp. Pharmacol. Physiol.* 2020, 47, 187–198.
  48. Lundberg, J.O.; Weitzberg, E. NO generation from inorganic nitrate and nitrite: Role in physiology, nutrition and therapeutics. *Arch. Pharmacol. Res.* 2009, 32, 1119–1126.
  49. Bahadoran, Z.; Ghasemi, A.; Mirmiran, P.; Azizi, F.; Hadaegh, F. Beneficial effects of inorganic nitrate/nitrite in type 2 diabetes and its complications. *Nutr. Metab.* 2015, 12, 16.
  50. McNally, B.; Griffin, J.L.; Roberts, L.D. Dietary inorganic nitrate: From villain to hero in metabolic disease? *Mol. Nutr. Food Res.* 2016, 60, 67–78.
  51. Walker, H.A.; McGing, E.; Fisher, I.; Böger, R.H.; Bode-Böger, S.M.; Jackson, G.; Ritter, J.M.; Chowienczyk, P.J. Endothelium-dependent vasodilation is independent of the plasma L-arginine/ADMA ratio in men with stable angina: Lack of effect of oral L-arginine on endothelial function, oxidative stress and exercise performance. *J. Am. Coll. Cardiol.* 2001, 38, 499–505.
  52. Schulman, S.P.; Becker, L.C.; Kass, D.A.; Champion, H.C.; Terrin, M.L.; Forman, S.; Ernst, K.V.; Kelemen, M.D.; Townsend, S.N.; Capriotti, A.; et al. L-arginine therapy in acute myocardial infarction: The Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) randomized clinical trial. *JAMA* 2006, 295, 58–64.
  53. Morris, S.M., Jr. Regulation of enzymes of urea and arginine synthesis. *Annu. Rev. Nutr.* 1992, 12, 81–101.
  54. Cynober, L.; Le Boucher, J.; Vasson, M.-P. Arginine metabolism in mammals. *J. Nutr. Biochem.* 1995, 6, 402–413.
  55. Adams, M.R.; Forsyth, C.J.; Jessup, W.; Robinson, J.; Celermajer, D.S. Oral L-arginine inhibits platelet aggregation but does not enhance endothelium-dependent dilation in healthy young men. *J. Am. Coll. Cardiol.* 1995, 26, 1054–1061.
  56. Mohan, S.; Wu, C.C.; Shin, S.; Fung, H.L. Continuous exposure to L-arginine induces oxidative stress and physiological tolerance in cultured human endothelial cells. *Amino Acids* 2012, 43, 1179–1188.
  57. Nyström, T.; Ortsäter, H.; Huang, Z.; Zhang, F.; Larsen, F.J.; Weitzberg, E.; Lundberg, J.O.; Sjöholm, Å. Inorganic nitrite stimulates pancreatic islet blood flow and insulin secretion. *Free Radic. Biol. Med.* 2012, 53, 1017–1023.
  58. Ghasemi, A.; Afzali, H.; Jeddi, S. Effect of oral nitrite administration on gene expression of SNARE proteins involved in insulin secretion from pancreatic islets of male type 2 diabetic rats. *Biomed. J.* 2021, in press.
  59. Roberts, L.D.; Ashmore, T.; Kotwica, A.O.; Murfitt, S.A.; Fernandez, B.O.; Feelisch, M.; Murray, A.J.; Griffin, J.L. Inorganic nitrate promotes the browning of white adipose tissue through the nitrate-nitrite-nitric oxide pathway. *Diabetes* 2015, 64, 471–484.
  60. Gheibi, S.; Jeddi, S.; Carlstrom, M.; Kashfi, K.; Ghasemi, A. Hydrogen sulfide potentiates the favorable metabolic effects of inorganic nitrite in type 2 diabetic rats. *Nitric Oxide Biol. Chem.* 2019.
  61. Kapil, V.; Khambata, R.; Jones, D.; Rathod, K.; Primus, C.; Massimo, G.; Fukuto, J.; Ahluwalia, A. The Noncanonical Pathway for In Vivo Nitric Oxide Generation: The Nitrate-Nitrite-Nitric Oxide Pathway. *Pharmacol. Rev.* 2020, 72, 692–766.
  62. Jeddi, S.; Yousefzadeh, N.; Afzali, H.; Ghasemi, A. Long-term nitrate administration increases expression of browning genes in epididymal adipose tissue of male type 2 diabetic rats. *Gene* 2021, 766, 145155.
  63. Tian, R.; Peng, R.; Yang, Z.; Peng, Y.-Y.; Lu, N. Supplementation of dietary nitrate attenuated oxidative stress and endothelial dysfunction in diabetic vasculature through inhibition of NADPH oxidase. *Nitric Oxide Biol. Chem.* 2020,



64. Aggarwal, H.; Pathak, P.; Singh, P.; Gayen, J.R.; Jagavelu, K.; Dikshit, M. Systemic Insulin Resistance and Metabolic Perturbations in Chow Fed Inducible Nitric Oxide Synthase Knockout Male Mice: Partial Reversal by Nitrite Supplementation. *Antioxidants* 2020, *9*, 736.
65. Norouzirad, R.; Gholami, H.; Ghanbari, M.; Hedayati, M.; González-Muniesa, P.; Jeddi, S.; Ghasemi, A. Dietary inorganic nitrate attenuates hyperoxia-induced oxidative stress in obese type 2 diabetic male rats. *Life Sci.* 2019, *230*, 188–196.
66. Jiang, H.; Torregrossa, A.C.; Potts, A.; Pierini, D.; Aranke, M.; Garg, H.K.; Bryan, N.S. Dietary nitrite improves insulin signaling through GLUT4 translocation. *Free Radic. Biol. Med.* 2014, *67*, 51–57.
67. Cermak, N.M.; Hansen, D.; Kouw, I.W.; van Dijk, J.W.; Blackwell, J.R.; Jones, A.M.; Gibala, M.J.; van Loon, L.J. A single dose of sodium nitrate does not improve oral glucose tolerance in patients with type 2 diabetes mellitus. *Nutr. Res.* 2015, *35*, 674–680.
68. Gilchrist, M.; Winyard, P.G.; Fulford, J.; Anning, C.; Shore, A.C.; Benjamin, N. Dietary nitrate supplementation improves reaction time in type 2 diabetes: Development and application of a novel nitrate-depleted beetroot juice placebo. *Nitric Oxide Biol. Chem.* 2014, *40*, 67–74.
69. Gilchrist, M.; Winyard, P.G.; Aizawa, K.; Anning, C.; Shore, A.; Benjamin, N. Effect of dietary nitrate on blood pressure, endothelial function, and insulin sensitivity in type 2 diabetes. *Free Radic. Biol. Med.* 2013, *60*, 89–97.
70. Faconti, L.; Mills, C.E. Cardiac effects of 6 months' dietary nitrate and spironolactone in patients with hypertension and with/at risk of type 2 diabetes, in the factorial design, double-blind, randomized controlled VaSera trial. *Br. J. Clin. Pharmacol.* 2019, *85*, 169–180.
71. Mills, C.E.; Govoni, V.; Faconti, L.; Casagrande, M.L.; Morant, S.V.; Crickmore, H.; Iqbal, F.; Maskell, P.; Masani, A.; Nanino, E. A randomised, factorial trial to reduce arterial stiffness independently of blood pressure: Proof of concept? The VaSera trial testing dietary nitrate and spironolactone. *Br. J. Clin. Pharmacol.* 2020, *86*, 891–902.
72. Soin, A.; Bock, G.; Giordano, A.; Patel, C.; Drachman, D. A Randomized, Double-Blind Study of the Effects of a Sustained Release Formulation of Sodium Nitrite (SR-nitrite) on Patients with Diabetic Neuropathy. *Pain Physician* 2018, *21*, 179–190.
73. Senefeld, J.W.; Wiggins, C.C.; Regimbal, R.J.; Dominelli, P.B.; Baker, S.E.; Joyner, M.J. Ergogenic Effect of Nitrate Supplementation: A Systematic Review and Meta-analysis. *Med. Sci. Sports Exerc.* 2020, *52*, 2250–2261.
74. Van De Walle, G.P.; Vukovich, M.D. The Effect of Nitrate Supplementation on Exercise Tolerance and Performance: A Systematic Review and Meta-Analysis. *J. Strength Cond. Res.* 2018, *32*, 1796–1808.
75. Li, D.; Nishi, S.K.; Jovanovski, E.; Zurbau, A.; Komishon, A.; Mejia, S.B.; Khan, T.A.; Sievenpiper, J.L.; Milicic, D.; Jenkins, A.; et al. Repeated administration of inorganic nitrate on blood pressure and arterial stiffness: A systematic review and meta-analysis of randomized controlled trials. *J. Hypertens.* 2020, *38*, 2122–2140.
76. Bahadoran, Z.; Norouzirad, R.; Mirmiran, P.; Gaeini, Z.; Jeddi, S.; Shokri, M.; Azizi, F.; Ghasemi, A. Effect of inorganic nitrate on metabolic parameters in patients with type 2 diabetes: A 24-week randomized double-blind placebo-controlled clinical trial. *Nitric Oxide Biol. Chem.* 2021, *107*, 58–65.
77. Shepherd, A.I.; Gilchrist, M.; Winyard, P.G.; Jones, A.M.; Hallmann, E.; Kazmierczak, R.; Rembialkowska, E.; Benjamin, N.; Shore, A.C.; Wilkerson, D.P. Effects of dietary nitrate supplementation on the oxygen cost of exercise and walking performance in individuals with type 2 diabetes: A randomized, double-blind, placebo-controlled crossover trial. *Free Radic. Biol. Med.* 2015, *86*, 200–208.
78. Mohler, E.R., 3rd; Hiatt, W.R.; Gornik, H.L.; Kevil, C.G.; Quyyumi, A.; Haynes, W.G.; Annex, B.H. Sodium nitrite in patients with peripheral artery disease and diabetes mellitus: Safety, walking distance and endothelial function. *Vasc. Med.* 2014, *19*, 9–17.
79. Greenway, F.L.; Predmore, B.L.; Flanagan, D.R.; Giordano, T.; Qiu, Y.; Brandon, A.; Lefer, D.J.; Patel, R.P.; Kevil, C.G. Single-dose pharmacokinetics of different oral sodium nitrite formulations in diabetes patients. *Diabetes Technol. Ther.* 2012, *14*, 552–560.

## Keywords

nitrate;nitrite;nitric oxide;ascorbic acid;type 2 diabetes